Beatriz Padrela , Amnah Mahroo , Mervin Tee , Markus Sneve , Paulien Moyaert , Oliver Geier , Joost Kuijer , Soetkin Beun , Wibeke Nordhøy , Yufei David Zhu , Mareike Buck , Daniel Hoinkiss , Simon Konstandin , Jörn Huber , Julia Wiersinga , Roos Rikken , Diederick de Leeuw , Håkon Grydeland , Lynette Tippett , Erin Cawston , Henk J.M.M. Mutsaerts
{"title":"DEveloping BBB-ASL as non-Invasive Early biomarker of Alzheimer's Disease (DEBBIE-AD): Study design","authors":"Beatriz Padrela , Amnah Mahroo , Mervin Tee , Markus Sneve , Paulien Moyaert , Oliver Geier , Joost Kuijer , Soetkin Beun , Wibeke Nordhøy , Yufei David Zhu , Mareike Buck , Daniel Hoinkiss , Simon Konstandin , Jörn Huber , Julia Wiersinga , Roos Rikken , Diederick de Leeuw , Håkon Grydeland , Lynette Tippett , Erin Cawston , Henk J.M.M. Mutsaerts","doi":"10.1016/j.cccb.2024.100308","DOIUrl":"10.1016/j.cccb.2024.100308","url":null,"abstract":"<div><h3>Introduction</h3><p>Arterial spin labeling (ASL) MRI, a non-invasive technique for imaging perfusion, now allows studying BBB permeability. The DEveloping BBB-ASL as a non-Invasive Early biomarker of Alzheimer's Disease (DEBBIE-AD) multi-cohort study integrates this modified BBB-ASL technique in several healthy and diseased populations (Table 1) to study methodological and clinical research questions (Table 2) on the ability of BBB-ASL as an early AD biomarker.</p></div><div><h3>Methods</h3><p>DEBBIE-AD will enroll various cohorts with subjective cognitive decline, mild cognitive impairment, and AD dementia, as well as age-matched healthy controls, at seven sites (Table 1). Our newly developed BBB-ASL sequence — implemented with the vendor-independent MRI framework gammaSTAR — will be added to multiple MRI protocols. The BBB-ASL sequence combines time-encoded multi-post labeling delay pseudo-continuous ASL with a multi-echo 3D GRASE readout, allowing estimating CBF, ATT, and the BBB time of exchange (Tex). Data analyses will be conducted using ExploreASL. Beyond MRI standard sequences, including T1w, T2w, FLAIR, DWI, the DEBBIE clinical outcomes include amyloid-PET and blood and CSF fluid biomarkers (Table 1).</p></div><div><h3>Expected Results</h3><p>Preliminary testing of the BBB-ASL has been conducted on 3T systems (different Siemens Heathineers scanners) in different cohorts at multiple sites. Data processing with ExploreASL includes FSL-FABBER4 for quantification, allowing harmonized image processing. An example of the mean and standard deviation Tex maps of two DEBBIE cohorts is shown in Figure 1 to illustrate the similarities of the Tex patterns from two cohorts of similar-aged healthy adults from different sites.</p></div><div><h3>Discussion</h3><p>The DEBBIE-AD study aims to provide evidence on the ability of BBB-ASL to measure BBB permeability and demonstrate its utility in AD-related pathologies. The presented sequence may provide novel and unique insights into the staging of BBB permeability changes in groups at greater risk of developing AD, which may, in turn, provide new targets for treatment.</p></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"6 ","pages":"Article 100308"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666245024001090/pdfft?md5=9642149bfb9a366c72c7f5f36b7c4edb&pid=1-s2.0-S2666245024001090-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142121920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Julia K. Gundersen , Fernando Gonzalez-Ortiz , Thomas Karikari , Bjørn-Eivind Kirsebom , Katrin Mertes , Henrik Zetterberg , Hlin Kvartsberg , Ole Morten Rønning , Berglind Gísladóttir , Kaj Blennow , Tormod Fladby
{"title":"Clinical value of plasma brain-derived tau and p-tau217 in acute ischemic stroke","authors":"Julia K. Gundersen , Fernando Gonzalez-Ortiz , Thomas Karikari , Bjørn-Eivind Kirsebom , Katrin Mertes , Henrik Zetterberg , Hlin Kvartsberg , Ole Morten Rønning , Berglind Gísladóttir , Kaj Blennow , Tormod Fladby","doi":"10.1016/j.cccb.2024.100291","DOIUrl":"10.1016/j.cccb.2024.100291","url":null,"abstract":"<div><h3>Introduction</h3><p>Diagnosis of acute ischemic stroke (AIS) as based on clinical examination and neuroimaging has limitations in determining subgroup aetiology and subsequent long-term motor and cognitive impairment. Identification of high-risk patients enables personalised prophylaxis and rehabilitation strategies. This study explores the clinical value of plasma brain-derived tau (BD-tau) and phosphorylated-tau217 (p-tau217), primarily associated with neurodegeneration, in identifying patients at risk of sequela after AIS.</p></div><div><h3>Methods</h3><p>We analysed a cohort of 193 patients admitted to the stroke unit at Akershus University Hospital in Oslo, Norway. Each patient received a diagnosis of AIS (n=102), transient ischemic attack (TIA, n=63) or stroke mimic (n=31). Patient characteristics were collected from hospital records. Biomarkers were quantified using Simoa HDX in venous blood sampled obtained the day after admission. Inpatient short-term outcomes, including stroke diameter on magnetic resonance imaging (MRI, n=134) and mini mental state examination (MMSE, n=153), were assessed prior to discharge. Non-parametric statistics, including Kruskal-Wallis and Kendall´s tau-b correlation tests were applied. Backwards stepwise linear regression analysis was used to determine the association between stroke diameter or MMSE and the biomarkers. A full model was fitted with explanatory variables as listen in table 1.</p></div><div><h3>Results</h3><p>BD-tau was significantly increased in AIS patients as compared to mimics (p=.004), whereas p- tau217 did not differentiate between the diagnostic groups. MRIs were available for 66 (64.7%) of AIS patients, of whom n=36 were diagnosed with cortical and n=30 with subcortical stroke. Cortical stroke diameter showed a strong correlation with BD-tau (fig. 1, <.001) and p-tau217 (=.003). In regression analysis, only BD-tau was found to be significantly associated with stroke diameter (table 1). Subcortical strokes were mot associated with any of the biomarkers. Furthermore, MMSE score correlated with BD-tau (fig. 2, <.001) and p-tau217 (<.001). In regression analysis, age was the strongest predictor of MMSE score, followed by p-tau217.</p></div><div><h3>Discussion</h3><p>Our findings suggest that blood-based BD-tau and p-tau217 have clinical potential in determining AIS subgroup aetiology and provide insights into cognitive impairment in AIS patients. These findings may have implications for rehabilitation and secondary prophylaxis after stroke.</p></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"6 ","pages":"Article 100291"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666245024000928/pdfft?md5=5bddfa9033ea3d027124dce3a85b8f25&pid=1-s2.0-S2666245024000928-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elijah Mak , Maria-Eleni Dounavi , Audrey Low , Graciela Muniz Terrera , Paresh Malhotra , Ivan Koychev , Clare Mackay , Brian Lawlor , Lorina Naci , Katie Wells , Craig Ritchie , Karen Ritchie , Li Su , Juan Gispert , John O'Brien
{"title":"Gene-dose effects of APOE ε4 on age-dependent increases in Peak Width of Skeletonised Mean Diffusivity during midlife","authors":"Elijah Mak , Maria-Eleni Dounavi , Audrey Low , Graciela Muniz Terrera , Paresh Malhotra , Ivan Koychev , Clare Mackay , Brian Lawlor , Lorina Naci , Katie Wells , Craig Ritchie , Karen Ritchie , Li Su , Juan Gispert , John O'Brien","doi":"10.1016/j.cccb.2024.100293","DOIUrl":"10.1016/j.cccb.2024.100293","url":null,"abstract":"<div><h3>Introduction</h3><p>The mechanistic associations between small vessel disease (SVD) and dementia are still poorly understood. The APOE ε4 allele, recognised as the strongest genetic risk factor for Alzheimer's disease, has been previously implicated in SVD, although it remains unclear whether this association is gene-dose dependent. An emerging neuroimaging biomarker of SVD is Peak Width of Skeletonised Mean Diffusivity (PSMD), obtained from histogram analyses of diffusion weighted imaging (DWI) datasets. Here, we investigated the relationship between APOE ε4 gene dose and PSMD, as a surrogate marker of SVD, in a group of cognitively normal middle-aged adults.</p></div><div><h3>Methods</h3><p>The study included data from 1954 asymptomatic middle-aged adults from the ALFA (ALzheimer and FAmilies) and PREVENT-Dementia cohorts (See Table 1 for sample characteristics). PSMD was calculated from the DWI datasets using a publicly available script, and harmonised using COMBAT to account for site-related differences. Using non-parametric permutation models, our primary analyses focused on the (a) comparison of group differences (APOE ε4 heterozygotes vs homozygotes vs non-carriers) in PSMD, adjusting for age, sex, years of formal education, and sites; and (b) potential interactions between APOE ε4 gene dose and age on PSMD values. Marginal predictions were used to estimate the earliest age at which differences might emerge between the APOE ε4 groups and non-carriers.</p></div><div><h3>Results</h3><p>There were no significant differences in PSMD values across the non-carriers (n=1,197), heterozygous carriers (n=659), and homozygous APOE ε4 carriers (n=98) (p = 0.6; Figure 1). However, there was a statistically significant interaction between APOE ε4 gene dose and age on PSMD. Specifically, homozygous APOE ε4 carriers exhibited a steeper increase in PSMD with age compared to non-carriers and heterozygous carriers (T = 4.7, p<0.01; Figure 2). Marginal effect analyses revealed higher PSMD values in homozygous APOE ε4 carriers at the estimated age of 57 relative to non-carriers and heterozygous carriers.</p></div><div><h3>Discussion</h3><p>Homozygosity for APOE ε4 could hasten dementia onset by accelerating age-dependent increases in PSMD. Future studies with a longitudinal design are warranted to clarify the molecular mechanisms through which the APOE ε4 allele influences PSMD and if this contributes to the contributes to the development of dementia.</p></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"6 ","pages":"Article 100293"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666245024000941/pdfft?md5=cd88fe07fcbde6e9a072b363c77002c1&pid=1-s2.0-S2666245024000941-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David Fresnais , Håkon Ihle-Hansen , Åsa Andersson , Erik Lundström , Brynjar Fure
{"title":"Cerebral Blood Flow in Mild Cognitive Impairment and Dementia: A Systematic Review and Meta- Analysis of Transcranial Doppler Studies","authors":"David Fresnais , Håkon Ihle-Hansen , Åsa Andersson , Erik Lundström , Brynjar Fure","doi":"10.1016/j.cccb.2024.100272","DOIUrl":"10.1016/j.cccb.2024.100272","url":null,"abstract":"<div><h3>Introduction</h3><p>Reduced cerebral blood flow has been associated with cognitive decline and incident dementia, with oxidative stress and reduced beta-amyloid clearance as possible mechanisms for neurodegeneration. Transcranial doppler sonography is a non-invasive tool for measuring cerebrovascular hemodynamics, including mean cerebral blood flow velocity. A systematic review and meta-analysis was performed to study mean cerebral blood flow velocity in the middle cerebral artery in persons with mild cognitive impairment and dementia compared to cognitively normal elderly.</p></div><div><h3>Methods</h3><p>We searched Pubmed, Embase, Cochrane Library, Epistemonikos, PsychINFO, and CINAHL according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. In total, 33439 titles and abstracts were screened, 86 articles were reviewed in full text, and 35 were included.</p></div><div><h3>Results</h3><p>Mean cerebral blood flow velocity in the middle cerebral artery was significantly lower in Alzheimer's disease (mean difference = 8.42; 95% confidence interval, -10.56 to -6.28), vascular dementia (mean difference = 11.75; 95% confidence interval, -14.68 to -8.82) and mild cognitive impairment (mean difference = 4.19; 95% confidence interval, -5.52 to -2.85) compared to cognitively normal elderly, see figures 1 – 3. Reduction in blood flow was equally pronounced in Alzheimer's disease and vascular dementia (mean difference = 2.79; 95% confidence interval, -0.78 to 6.35).</p></div><div><h3>Discussion</h3><p>Cerebral blood flow velocity is reduced in Alzheimer's disease, vascular dementia and MCI, with more pronounced disturbances in dementia.</p></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"6 ","pages":"Article 100272"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666245024000734/pdfft?md5=3d77396ce306f550455e394a8e8f5380&pid=1-s2.0-S2666245024000734-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142122213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atticus H Hainsworth , Riccardo Paracampo , Anders Wallin
{"title":"Editorial. CCCB: The journal at age 5","authors":"Atticus H Hainsworth , Riccardo Paracampo , Anders Wallin","doi":"10.1016/j.cccb.2024.100368","DOIUrl":"10.1016/j.cccb.2024.100368","url":null,"abstract":"<div><div>The journal <em>Cerebral Circulation, Cognition & Behavior</em> (<em>CCCB</em>) was conceived to serve at the border zone between the fields of cognition, brain vascular function, cerebrovascular disease and neurodegeneration. An umbrella term often used for this spectrum of disorders or conditions is Vascular contributions to Cognitive Impairment and Dementia (VCID). The journal was launched in 2020. Since then <em>CCCB</em> has published 146 articles and achieved listing on PubMed, Web of Science, Directory of Open Access Journals and Scopus. A Web of Science journal impact factor of 1.9 for 2023 has recently been released. The journal is online-only, with Gold Open Access. The number of full-text downloads is high, averaging 1200 per article.</div></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"7 ","pages":"Article 100368"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142908006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Philip B. Gorelick , Atticus H. Hainsworth , Anders Wallin
{"title":"What will it take to achieve brain health globally?","authors":"Philip B. Gorelick , Atticus H. Hainsworth , Anders Wallin","doi":"10.1016/j.cccb.2024.100209","DOIUrl":"10.1016/j.cccb.2024.100209","url":null,"abstract":"<div><p>Brain health initiatives and programs are gaining traction worldwide. Some are clinically based, others research based, and some are a combination of clinical and research action plans. Achievement of global brain health is a challenging endeavor with prerequisites including but not limited to multidisciplinary and multisectoral approaches, strengthening of neurologic policies at local and regional levels, global advocacy, leadership and collaboration amongst stakeholders, development of technical and guidance documents, and strengthening and interpretation of the relevant evidence. Over 1 billion persons worldwide are impacted by neurologic disorders, and brain health initiatives are needed to curb the human suffering and cost of these disorders. We provide a brief review of select brain health initiatives and programs and offer possible steps to achieve brain health globally.</p></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"6 ","pages":"Article 100209"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666245024000102/pdfft?md5=dc0f13b3eaf7edb4c05cf761efe22c4b&pid=1-s2.0-S2666245024000102-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gurpreet Kaur Hansra , Tharusha Jayasena , Satoshi Hosoki , Anne Poljak , Ben Chun Pan Lam , Ruslan Rust , Abhay Sagare , Berislav Zlokovic , Anbupalam Thalamuthu , Perminder S. Sachdev
{"title":"Fluid biomarkers of the neurovascular unit in cerebrovascular disease and vascular cognitive disorders: A systematic review and meta-analysis","authors":"Gurpreet Kaur Hansra , Tharusha Jayasena , Satoshi Hosoki , Anne Poljak , Ben Chun Pan Lam , Ruslan Rust , Abhay Sagare , Berislav Zlokovic , Anbupalam Thalamuthu , Perminder S. Sachdev","doi":"10.1016/j.cccb.2024.100216","DOIUrl":"10.1016/j.cccb.2024.100216","url":null,"abstract":"<div><h3>Background</h3><p>The disruption of the neurovascular unit (NVU), which maintains the integrity of the blood brain barrier (BBB), has been identified as a critical mechanism in the development of cerebrovascular and neurodegenerative disorders. However, the understanding of the pathophysiological mechanisms linking NVU dysfunction to the disorders is incomplete, and reliable blood biomarkers to measure NVU dysfunction are yet to be established. This systematic review and meta-analysis aimed to identify biomarkers associated with BBB dysfunction in large vessel disease, small vessel disease (SVD) and vascular cognitive disorders (VCD).</p></div><div><h3>Methods</h3><p>A literature search was conducted in PubMed, EMBASE, Scopus and PsychINFO to identify blood biomarkers related to dysfunction of the NVU in disorders with vascular pathologies published until 20 November 2023. Studies that assayed one or more specific markers in human serum or plasma were included. Quality of studies was assessed using the Newcastle-Ottawa Quality Assessment Scale. Effects were pooled and methodological heterogeneity examined using the random effects model.</p></div><div><h3>Results</h3><p>A total of 112 studies were included in this review. Where study numbers allowed, biomarkers were analysed using random effect meta-analysis for VCD (1 biomarker; 5 studies) and cerebrovascular disorders, including stroke and SVD (9 biomarkers; 29 studies) while all remaining biomarkers (<em>n</em> = 17 biomarkers; 78 studies) were examined through qualitative analysis. Results of the meta-analysis revealed that cerebrospinal fluid/serum albumin quotient (Q-Alb) reliably differentiates VCD patients from healthy controls (MD = 2.77; 95 % CI = 1.97–3.57; <em>p</em> < 0.0001) while commonly measured biomarkers of endothelial dysfunction (VEGF, VCAM-1, ICAM-1, vWF and E-selectin) and neuronal injury (NfL) were significantly elevated in vascular pathologies. A qualitative assessment of non-meta-analysed biomarkers revealed NSE, NfL, vWF, ICAM-1, VCAM-1, lipocalin-2, MMP-2 and MMP-9 levels to be upregulated in VCD, although these findings were not consistently replicated.</p></div><div><h3>Conclusions</h3><p>This review identifies several promising biomarkers of NVU dysfunction which require further validation. A panel of biomarkers representing multiple pathophysiological pathways may offer greater discriminative power in distinguishing possible disease mechanisms of VCD.</p></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"6 ","pages":"Article 100216"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666245024000175/pdfft?md5=2fc4c46f54237bc876668e0051ea5020&pid=1-s2.0-S2666245024000175-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139967097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuvthi Lutchman , Rajiv Mahajan , Suzanne M. Cosh , Katie Harris , Christophe Tzourio , Phillip J. Tully
{"title":"Under pressure: A systematic review of the association between blood pressure variability with depression and anxiety","authors":"Yuvthi Lutchman , Rajiv Mahajan , Suzanne M. Cosh , Katie Harris , Christophe Tzourio , Phillip J. Tully","doi":"10.1016/j.cccb.2024.100228","DOIUrl":"https://doi.org/10.1016/j.cccb.2024.100228","url":null,"abstract":"<div><p>Blood pressure variability (BPV) impacts brain health by influencing brain structure and cerebrovascular pathologies, though the mechanisms are poorly understood. Changes in the cerebrovasculature may lead to late-onset depression, cognitive impairment, and dementia, however the relationship between BPV with depression and anxiety remains unclear, due to methodological differences and inconsistencies in past research. This review aims to clarify the association between BPV with depression and anxiety in adults to inform understandings of the mechanisms implicating BPV in cognitive health. A systematic search from inception through to January 2024 was performed on Embase, PubMed, PsycINFO, and Web of Science. Studies that assessed BPV quantified by beat-to-beat, 24-hour, or visit-to-visit were eligible if the standardised assessment of depression and/or anxiety were reported as a linear association, or mean differences across control and affect groups. A total of 14 articles reporting on 13 samples and <em>N</em> = 5055 persons met the inclusion criteria (median female proportion = 61 %, range 0 % - 76 %). A meta-analysis was not possible due to methodological heterogeneity in BPV measurements and metrics across studies. Mixed results were observed across depression studies with inconsistencies and variation in the direction, strength of association, and BPV metric. There was weak evidence from only three studies to support a linear association between systolic coefficient of variation and anxiety. Collectively, the findings contribute to understanding the association between BPV and brain health, suggesting that any relationship between BPV and brain structures critical for cognitive function are independent of depression and only modestly implicate anxiety.</p></div>","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"6 ","pages":"Article 100228"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666245024000291/pdfft?md5=d347ef9f4218320c499e7b0240f9741d&pid=1-s2.0-S2666245024000291-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141314449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alberto De Luca , Hugo Kuijf , Lieza Exalto , Geert-Jan Biessels
{"title":"ANALYZING MULTIMODAL MRI AT TRACT-LEVEL WITH NEURAL NETWORKS ENHANCES THE PREDICTION OF COGNITIVE PERFORMANCE IN MEMORY CLINIC PATIENTS WITH SMALL VESSEL DISEASE","authors":"Alberto De Luca , Hugo Kuijf , Lieza Exalto , Geert-Jan Biessels","doi":"10.1016/j.cccb.2022.100053","DOIUrl":"https://doi.org/10.1016/j.cccb.2022.100053","url":null,"abstract":"","PeriodicalId":72549,"journal":{"name":"Cerebral circulation - cognition and behavior","volume":"6 ","pages":"Article 100053"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666245022000186/pdfft?md5=185de1532cea30527da5735dbfab0435&pid=1-s2.0-S2666245022000186-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}